Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective

about

Anti-hyperglycemic activity of selenium nanoparticles in streptozotocin-induced diabetic rats What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus.

P2860

Q36244284-CADD9360-4D1F-4D6F-BB76-96C5C023810B Q39038925-1A1511ED-ADD8-431D-B2ED-09F5560F2B6B

P2860

Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective

Item

http://www.wikidata.org/entity/Q38285665

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Efficacy and tolerability of G ...... ellitus: an Indian perspective

@en

type

Item

label

Efficacy and tolerability of G ...... ellitus: an Indian perspective

@en

prefLabel

Efficacy and tolerability of G ...... ellitus: an Indian perspective

@en

P1476

Efficacy and tolerability of G ...... ellitus: an Indian perspective

@en

P2093

Mala Dharmalingam

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

10-year follow-up of intensive glucose control in type 2 diabetes

Biology of incretins: GLP-1 and GIP

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Current glycemic status and diabetes related complications among type 2 diabetes patients in India: data from the A1chieve study.

Minireview: the glucagon-like peptides.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

P304

159-165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2042018814552657

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25489471

http://www.w3.org/2001/XMLSchema#string

P921

India

P932

4257981

http://www.w3.org/2001/XMLSchema#string

Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective

about

P2860

P2860

Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932